αHER2-E-P125A demonstrated longer t1/2 than endostatin in vivo, a superior anti-angiogenic efficacy, and greater anti-tumor efficacy than anti-HER2 antibody, endostatin, or αHER2-fused to wild type endostatin against HER2+ breast cancer xenografts [15,16]. This evidence concerns the gene ERBB2 and breast cancer.